KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Revenue (2017 - 2026)

Aquestive Therapeutics has reported Revenue over the past 9 years, most recently at $13.0 million for Q4 2025.

  • For Q4 2025, Revenue rose 9.67% year-over-year to $13.0 million; the TTM value through Dec 2025 reached $44.5 million, down 22.61%, while the annual FY2025 figure was $44.5 million, 22.61% down from the prior year.
  • Revenue for Q4 2025 was $13.0 million at Aquestive Therapeutics, up from $12.8 million in the prior quarter.
  • Over five years, Revenue peaked at $20.1 million in Q2 2024 and troughed at $2.0 million in Q2 2021.
  • A 5-year average of $11.5 million and a median of $12.0 million in 2024 define the central range for Revenue.
  • Biggest five-year swings in Revenue: skyrocketed 300.0% in 2021 and later crashed 50.23% in 2025.
  • Year by year, Revenue stood at $11.1 million in 2021, then decreased by 3.57% to $10.7 million in 2022, then grew by 23.63% to $13.2 million in 2023, then decreased by 10.14% to $11.9 million in 2024, then grew by 9.67% to $13.0 million in 2025.
  • Business Quant data shows Revenue for AQST at $13.0 million in Q4 2025, $12.8 million in Q3 2025, and $10.0 million in Q2 2025.